1. Ivashkin VT, Shirokova EN, Mayevskaya MV, et al. Clinical recommendations of the Russian Gastroenterological Association and the Russian Society for the Study of the Liver for the diagnosis and treatment of cholestasis. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2015;25(2):41-57. (In Russ.) Ивашкин В. Т., Широкова Е. Н., Маевская М. В. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и Российского общества по изучению печени по диагностике и лечению холестаза. Российский журнал гастроэнтерологии, гепатологии, коло-проктологии. 2015;25(2):41-57.
2. Yokoda RT, Rodriguez EA. Review: Pathogenesis of cholestatic liver diseases. World J Hepatol. 2020;12(8):423-35. doi:10.4254/wjh.v12.i8.423.
3. Polunina TE. Therapeutic approaches to the treatment of cholestatic liver diseases. Therapy. 2019;3:99-108. (In Russ.) Полунина Т. Е. Терапевтические подходы к лечению холестатических заболеваний печени. Терапия. 2019;3:99-108. doi:10.18565/therapy.2019.3.99-108.
4. Sherlock S, Dooley J. Diseases of the liver and biliary tract. Moscow: Geotar Medicine. 1999. p. 859. (In Russ.) Шерлок Ш., Дули Дж. Заболевания печени и желчных путей. Москва: Гэотар Медицина. 1999. с. 859.
5. Khungar V, Goldberg DS. Liver Transplantation for Cholestatic Liver Diseases in Adults. Clin Liver Dis. 2016;20:191-203. doi:10.1016/j.cld.2015.08.011.
6. Lazaridis KN, LaRusso NF. The Cholangiopathies. Mayo Clin Proc. 2015;90:791-800. doi:10.1016/j.mayocp.2015.03.017.
7. Sclair SN, Fiel MI, Wu HS, et al. Increased hepatic progenitor cell response and ductular reaction in patients with severe recurrent HCV post-liver transplantation. Clin Transplant. 2016;30:722-30. doi:10.1111/ctr.12740.
8. Jalan-Sakrikar N, De Assuncao TM, Lu J, et al. Hedgehog Signaling Overcomes an EZH2-Dependent Epigenetic Barrier to Pro-mote Cholangiocyte Expansion. PLoS One.2016;11:e0168266. doi:10.1371/journal.pone.0168266.
9. Tan M, Tang C, Zhang Y, et al. SIRT1/PGC-1α signaling protects hepatocytes against mitochondrial oxidative stress induced by bile acids. Free Radic Res. 2015;49:935-45. doi: 10.3109/10715762.2015.1016020.
10. Pinzani M, Luong TV. Pathogenesis of biliary fibrosis. Biochim Biophys Acta Mol Basis Dis. 2018;1864:1279-83. doi:10.1016/j.bbadis.2017.07.026.
11. Polunina TE. Cholestasis: pathophysiological mechanisms of development, diagnosisand treatment. Effective pharmacology. Gastroenterology. 2012;5:10-4. (In Russ.) Полунина Т. Е. Холестаз: патофизиологические механизмы развития, диагностика и лечение. Эффективная фармакология. Гастроэнтерология. 2012;5:10-4.
12. Paumgartner G. Medical treatment of cholestatic liver diseases: From pathobiology to pharmacological targets. World J Gastroenterol. 2006;12(28):4445-51.
13. Pedersen MR, Mayo MJ. Managing the Symptoms and Complications of Cholestasis. Clinical liver disease. 2020;15:3.
14. Hilscher MB, Kamath PS, Eaton JE. Cholestatic Liver Diseases: A Primer for Generalists and Subspecialists. 2020 Mayo Foundation for Medical Education and Research. MayoClin Proc. 2020;95(10):2263-79. doi:10.1016/j.mayocp.2020.01.015.
15. Volynets GV, Khavkin AI. Ursodeoxycholic acid and liver diseases. The attending physician. 2020;6:62-8. (In Russ.) Волынец Г. В., Хавкин А. И. Урсодезоксихолевая кислота и болезни печени. Лечащий врач. 2020;6:62-8. doi:10.26295/OS.2020.75.99.012.
16. Baranovsky AYu, Raikhelson KL, Semenov NV, Solonitsyn EG. Principles of treatment of cholestatic liver diseases. The attending physician. 2012;(07):43-50. (In Russ.) Барановский А. Ю., Райхельсон К. Л., Семенов Н. В., Солоницин Е. Г. Принципы лечения холестатических заболеваний печени. Лечащий врач. 2012;(07):43-50.
17. Beuers U, Trauner M, Jansen P, Poupon R. New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. J Hepatol. 2015;62(1 Suppl):S25-37. doi:10.1016/j.jhep.2015.02.023.
18. Heathcote EJ. Diagnosis and management of cholestatic liver disease. Clin. Gastroenterol. Hepatol. 2007;5(7):776-82.
19. Gasser RW. Cholestasis and metabolic bone disease — a clinical review. Wien. Med. Wochenschr. 2008;158(19-20):553-7.
20. EASL. Clinical Practice Guidelines: Management of cholestatic liver diseases. Journal of Hepatology. 2009;5:237-67.
21. Diagnosis and management tactics of primary biliary cholangitis: clinical recommendations EASL European Association for the Study of the Liver (EASL). Journal of Hepatology. 2017;67:145-72. (In Russ.) Диагностика и тактика ведения первичного билиарного холангита: клинические рекомендации EASL Европейская ассоциация по изучению печени (EASL). Журнал гепатологии. 2017;67:145-72.
